Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...

Participants in a randomized controlled trial who took liraglutide were more likely to develop gallbladder stones and other complications of the gallbladder and biliary tract vs. those who took ...

Fourteen years ago, the older drug cousin of semaglutide (Ozempic and Wegovy) came onto the market. The drug, liraglutide, is sold under the brand names Victoza and Saxenda. The class of drugs ...

Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less than 7% than the sulfonylurea glimepiride or the DPP-IV inhibitor sitagliptin, according to ...

New trial shows liraglutide helps reduce BMI in children aged 6 to 12 with obesity, but side effects prompt further study Study: Liraglutide for Children 6 to <12 Years of Age with Obesity — A ...

New Phase 3a results demonstrate that IDegLira, an investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of patients with type 2 diabetes, ...

New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its ...

Patients with obesity or type 2 diabetes (T2D) who stuck with their medication for a year lost more weight with semaglutide than with liraglutide, a new study reported. Researchers at the Cleveland ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

1.8% from baseline versus 1.4% for insulin degludec and 1.2% for liraglutide (p<0.0001). The average HbA1c at the end of the trial was 6.4% for IDegLira, 6.9% with insulin degludec and 7.1% with ...